Member Info for LiveLongnProsper

Prof John Bell on mass testing now ... started about 07:35
Saliva test just mentioned
Sens / Spec, false neg / pos, etc.
Not mentioned us yet ..
GLA

Yep, sounds like us ...
“new technologies coming on stream now”
“which we are buying”
“only have to use saliva”
“results in 10 mins”
“being tested in Porton Down”
but ... "working with dozens of companies"
GLA

and another 250k at the bell ...!
Aug 18 2020, 16:29 240.00 250,000 238.00 240.00 Buy £600,000.00
GLA

the 250k buy @ 235 ...?
Aug 18 2020, 14:25 235.00 250,000 230.00 234.00 Buy £587,500.00
GLA

@13thM, yes, but need mass testing for certainty of genuine negative (or to isolate positives), 'bio id' also (albeit vaguely) mentioned.
GLA

All those asymptomatic folks are effectively false negatives! Intelligent discussion, whatever your politics!
Need for mass antigen testing.
GLA

https://abetterlifepharma.com/investors/#latestnews
BetterLife have done a placing the proceeds from which will be used for working capital and the clinical trials work for their AP-003 inhaled interferon a2b (IFNa2b) – planned to start in 6-10 weeks.
Think they’re still on trading halt though while they sort out the acquisition of Altum.
GLA

And another £200k+ ...
2020-08-11T15:42:42.837 GBX 209.874 100000 209874 Off-Book SINT TNCP
(Note - mic code SINT)
GLA

2020-08-11T15:16:58.270 GBX 209.874 300000 629622 Off-Book SINT TNCP
Investment co. buying on behalf of client?
Positions continuing to be taken.
GLA

Yep, Radio4 Inside Health, not really enough info to determine if AVCT. Not clear if Antigen or Antibody, and no details on equipment etc. Given AVCT likely disposable consumer device or Mass Spec it seemed unlikely to be ours? To be honest pretty poor report in terms of detail.
GLA

BetterLife reported on an (uncontrolled) trial in China published on 15th of May. So they now have to do a properly controlled phase II/III trial. So way behind.
Our phase II trial was double-blind placebo controlled in the NHS (‘gold standard’) – with the positive results we should anticipate expedited approval soon. My view, of course DYOR.
BetterLife’s new Scientific Advisory Board member Dr Eleanor Fish has been quoted as saying that "rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the 'first responders' in terms of treatment. Interferons have been approved for clinical use for many years, so the strategy would be to 'repurpose' them for severe acute virus infections…”.
BetterLife have only just completed the acquisition of Altum who had the patent for AP-003 (inhaled IFNa2b).
GLA

Some of the larger trades reported today with mic code SINT.
tradeTime currency price volume tradeValue type micCode tradeType
2020-08-03T09:12:29.000 GBX 130 500000 650000 Off-Book SINT LRGS
2020-08-03T16:12:04.363 GBX 136 312601 425137.36 Off-Book XOFF
2020-08-03T13:09:28.160 GBX 129 256523 330914.67 Off-Book SINT BENC TNCP LRGS
2020-08-03T11:12:43.023 GBX 129 256523 330914.67 Off-Book AIMX
2020-08-03T10:30:33.000 GBX 129 200000 258000 Off-Book SINT LRGS
2020-08-03T12:19:51.400 GBX 130.063 200000 260126 Off-Book AIMX LRGS
2020-08-03T08:59:54.000 GBX 130 200000 260000 Off-Book SINT LRGS
2020-08-03T12:19:14.280 GBX 130.75 200000 261500 Off-Book AIMX LRGS
2020-07-31T16:07:22.000 GBX 150 108119 162178.5 Off-Book XOFF N
2020-08-03T10:21:04.000 GBX 129 100000 129000 Off-Book SINT LRGS
2020-08-03T07:51:12.000 GBX 136 100000 136000 Off-Book SINT LRGS
2020-08-03T08:25:18.000 GBX 132.5 100000 132500 Off-Book SINT LRGS
Mic code SINT MiFID II definition – “an investment firm which, on an organised, frequent and systematic basis, deals on own account by executing client orders outside a regulated market or an MTF or an OTF without operating a multilateral system".
I read that as an investment firm trading using their own account but on behalf of a client? Please correct as necessary.
Any thoughts on ‘the client’.
GLA

22/07/20 We have “begun work with the UK government's CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry ("BAMSTM") laboratory assay developed with Adeptrix”.
“The work with the CONDOR programme will commence immediately to evaluate the test performance using real patient samples and will quickly progress to full clinical validation”.
“I am also very pleased that the CONDOR programme will support the clinical validation of the rapid saliva-based COVID-19 antigen test strip that we are developing with Cytiva. This, combined with other collaborations that we are putting in place, will provide us with access to a sufficient number of COVID-19 patient samples to allow us to quickly clinically validate the saliva rapid test”.
“I look forward to providing further updates in due course”.
So from this RNS, “updates in due course”, i.e. when the government CONDOR process is completed – BAMS first then saliva test.
Tests announced today probably just a few days ahead of us in the CONDOR queue?
29/07/20 From the Daewoong RNS, “I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly".
So a ‘due course’ 2 weeks ago and a ‘shortly’ last week. Yeh, I know, we had a ‘very soon’ on 13/07/20!
For scientists, as opposed to mathematicians, the average of ‘due course’, ‘shortly’ and ‘very soon’ could be ‘this week’ (haha)? A little tense just now, but nevertheless exciting times.
GLA

Some way to go!

@NOZ85, great find. Thought it deserved it's own heading, hope you don't mind.
We know BetterLife are desperate to catchup with / benefit from SNG. Interesting quote from Dr Fish ...
"Fish says that once data is in from a large clinical trial on Interferon’s effectiveness, it will likely be used in tandem with other medications that are currently showing effectiveness in treating coronavirus. She foresees a COVID-19 ****tail, much like the medication ****tails used to treat HIV, which may include the antiviral Remdesivir and Interferon at the beginning of the infection and possibly a steroid like Dexamethasone at the back-end. Dexamethasone was recently shown to significantly reduce death rates from the virus".

We (SNG) have the data (maybe not a "large" trial?) and it demonstrates efficacy. BetterLife's AP-003 has some way to!
GLA

Just listened again, even better the second time, detail from about 17:12 Radio4 PM programme ...
"What's needed is an instant virus test"
"That can be using Saliva"
"Absolute game changer"
"On the market in the next few weeks"
"What a difference to holidays"
David from WHO must know who we are and what we've got and he wants some, like a lot ...!
GLA

From about 17:08 - David from WHO.
Stresses the importance of Saliva tests, has been in touch with research co.'s, expects available in a few weeks, 'game changer'.
GLA

Jul 27 2020, 14:47 220.00 300,000 220.00 224.00 Sell £660,000.00
Jul 27 2020, 14:47 220.00 250,000 220.00 224.00 Sell £550,000.00
Looks like 2 big sells?
GLA

Options ...
https://www.synairgen.com/wp-content/uploads/2020/06/200619-Grant-of-Options.pdf
RM has 3.5m.
GLA

Err .., SNG001 not a vaccine, is a treatment!
On the subject of treatments (not vaccines), is there any competition?
Remdesivir efficacy debateable. Dexamethasone maybe as a last resort under certain circumstances. Hydroxychloroquine – moving rapidly on.
Are there any more?
SNG001 actually works …
SNG001, just proven in phase II trial.
Broker target £3.60, i.e. mcap ~£540m, seems reasonable, maybe a bit cautious.
GLA and please DYOR